Andrew D. Zelenetz

Andrew Zelenetz is a senior lymphoma specialist at MSK renowned for his contributions to molecular profiling of follicular lymphoma and leadership of NCCN lymphoma treatment guidelines. His research has investigated clonal evolution of FL and mechanisms of histologic transformation using molecular tracking techniques. He has contributed to defining optimal frontline treatment with obinutuzumab-based regimens and led studies evaluating novel agents in relapsed/refractory FL. He serves on multiple national and international guideline committees and is recognized as a leader in evidence-based lymphoma care.